Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in US clinical trials in the treatment of dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.
Developing multicellular treatments—with integrity
To fulfill Aastrom’s mission of helping people with DCM realize the promise of patient-specific stem cell therapy, we hold fast to our values, always using rigorous scientific methods to test hypotheses and evaluate our products’ potential. Personal integrity and accountability to our stakeholders are the foundations of our work, and we seek to practice transparency and openness in our dealings with each other, our patients, and our investors.